Oral Bioavailability

The thermodynamic saturation concentration of a compound in aqueous media, directly limiting the amount of drug available for absorption across the gastrointestinal epithelium.

• Intrinsic solubility refers to the equilibrium solubility of the neutral form, a fundamental physicochemical constant
• pH-dependent solubility is governed by the Henderson-Hasselbalch equation, where ionizable groups dramatically alter solubility in different GI compartments
• The Biopharmaceutics Classification System (BCS) uses solubility as a primary axis, classifying compounds as highly soluble when the highest dose dissolves in ≤250 mL of aqueous media across pH 1–7.5
• Poor solubility leads to dissolution rate-limited absorption, described by the Noyes-Whitney equation: dM/dt = (DA/h)(Cs - C)
• Key thresholds: Compounds with solubility <10 μg/mL typically exhibit significant absorption liabilities

The partition coefficient between an organic phase (octanol) and aqueous phase, quantifying a molecule's hydrophobic character and its ability to cross lipid bilayer membranes.

• LogP measures partitioning of the neutral species; LogD measures the distribution coefficient at a specific pH, accounting for ionization
• Optimal oral absorption typically occurs in the LogD₇.₄ range of 1–3, balancing membrane permeability with aqueous solubility
• Excessively high LogP (>5) correlates with poor solubility, high metabolic clearance, and promiscuous off-target binding
• Lipophilicity drives passive transcellular permeability, the dominant absorption route for most small molecules
• Lipophilic ligand efficiency (LLE) = pIC₅₀ - LogP, a metric balancing potency against lipophilicity to optimize drug-likeness

The acid dissociation constant determines the ratio of ionized to neutral species at any given pH, critically influencing both solubility and passive membrane permeability.

• The pH-partition hypothesis states that only the uncharged form of a drug crosses biological membranes at appreciable rates
• Weak acids with pKa 3–7 and weak bases with pKa 7–10 exhibit complex, region-dependent absorption profiles along the GI tract
• Ion trapping occurs when a compound becomes charged in a compartment from which it cannot readily diffuse back, concentrating drug in specific tissues or GI segments
• Zwitterionic compounds possess both acidic and basic groups, exhibiting unique solubility-permeability relationships that deviate from classical pH-partition theory
• The Rule of Five implicitly addresses ionization through its hydrogen bond donor/acceptor counts, which correlate with desolvation penalties

The total number of hydrogen bond donors (HBD) and acceptors (HBA) determines the energetic cost of desolvating a molecule to cross the lipid bilayer, a key component of Lipinski's Rule of Five.

• Lipinski thresholds: HBD ≤ 5, HBA ≤ 10; exceeding these correlates with reduced permeability
• Each hydrogen bond must be broken with water before membrane partitioning, imposing a significant energetic penalty estimated at 0.5–1.5 kcal/mol per bond
• Polar surface area (PSA) serves as a surrogate metric; a PSA >140 Ų strongly predicts poor oral absorption and limited blood-brain barrier penetration
• Intramolecular hydrogen bonds can shield polarity, allowing compounds to violate HBD/HBA rules while maintaining acceptable permeability—a phenomenon exploited in macrocyclic and beyond-Rule-of-5 drugs
• Veber's rules propose rotatable bond count ≤10 and PSA ≤140 Ų as superior oral bioavailability predictors compared to molecular weight alone

Molecular weight (MW) and conformational flexibility influence passive diffusion rates, solubility, and the probability of successful target binding.

• Lipinski's MW threshold: ≤500 Da; larger molecules face compounded solubility and permeability challenges
• Diffusion coefficient (D) is inversely proportional to molecular radius via the Stokes-Einstein equation, directly reducing membrane flux for larger molecules
• Rotatable bond count quantifies conformational flexibility; Veber identified ≤10 rotatable bonds as a superior oral bioavailability filter compared to MW
• High flexibility imposes an entropic penalty upon binding and increases the probability of adopting conformations incompatible with membrane permeation
• Beyond Rule of Five (bRo5) compounds—including macrocycles, proteolysis-targeting chimeras (PROTACs), and natural products—often violate MW limits while maintaining oral activity through chameleonic behavior and intramolecular hydrogen bonding

The susceptibility of a compound to first-pass metabolism in the liver and gut wall, which can eliminate a significant fraction of an orally administered dose before reaching systemic circulation.

• First-pass extraction ratio (E) = CLₕₑₚ/Qₕₑₚ, where CLₕₑₚ is hepatic clearance and Qₕₑₚ is hepatic blood flow (~1.5 L/min in humans)
• Oral bioavailability F = Fₐ × F_g × Fₕ, where Fₐ is fraction absorbed, F_g is gut wall escape, and Fₕ is hepatic escape
• CYP3A4 is the dominant metabolic enzyme, responsible for oxidizing >50% of marketed drugs; its expression in both enterocytes and hepatocytes creates a dual metabolic barrier
• Metabolic soft spots—sites of rapid oxidative metabolism—can be identified computationally and blocked with strategic fluorine substitution or ring modifications
• Intrinsic clearance (CLᵢₙₜ) measured in liver microsomes or hepatocytes provides the primary in vitro correlate for predicting in vivo hepatic extraction